Evidence map›Paper›PMID 34695199›Full record

ArticleBlood2022

Whole-genome landscape of adult T-cell leukemia/lymphoma.

Yasunori Kogure, Takuro Kameda, Junji Koya, Makoto Yoshimitsu, Kisato Nosaka, Jun-Ichirou Yasunaga, Yoshitaka Imaizumi, Mizuki Watanabe, Yuki Saito, Yuta Ito and 36 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 91 citations in OpenAlex.

  1. Trial
  2. Article
  3. Loss of HTLV-1-specific CD8Blood neoplasia · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. mGenes to cells : devoted to molecular & cellular mechanisms · 2025
    Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

46 authors at 15 institutions in 2 countries.

Yasunori KogureDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0003-1158-5131
Takuro KamedaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0003-0100-1710
Junji KoyaDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0002-0605-1226
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.ORCID 0000-0002-5935-0385
Kisato NosakaDepartment of Hematology, Rheumatology, and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID 0000-0001-6682-2451
Jun-Ichirou YasunagaDepartment of Hematology, Rheumatology, and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID 0000-0002-7939-2080
Yoshitaka ImaizumiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.ORCID 0000-0002-2954-5691
Mizuki WatanabeDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-4030-4653
Yuki SaitoDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0003-2686-9604
Yuta ItoDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Marni B McClureDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0002-0807-4368
Mariko TabataDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0002-8013-7327
Sumito ShingakiDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0002-4249-5000
Kota YoshifujiDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Kenichi ChibaDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Ai OkadaDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Nobuyuki KakiuchiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0003-4893-5414
Yasuhito NannyaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6526-0992
Ayako KamiuntenDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-6347-4305
Yuki TahiraDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0001-6640-4559
Keiichi AkizukiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0003-0031-3456
Masaaki SekineDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0001-5481-3451
Kotaro ShideDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-0046-3254
Tomonori HidakaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-7018-3653
Yoko KubukiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-0763-9136
Akira KitanakaDepartment of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan.ORCID 0000-0002-2659-8405
Michihiro HidakaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Nobuaki NakanoDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.ORCID 0000-0001-9826-7616
Atae UtsunomiyaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.ORCID 0000-0002-8843-406X
R Alejandro SicaDepartment of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.ORCID 0000-0001-8877-4470
Ana Acuna-VillaordunaDepartment of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.ORCID 0000-0003-0180-2972
Murali JanakiramDepartment of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.ORCID 0000-0001-9323-8007
Urvi ShahDepartment of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.ORCID 0000-0001-8419-1091
Juan Carlos RamosDivision of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.
Tatsuhiro ShibataDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0002-0477-210X
Kengo TakeuchiDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID 0000-0002-1599-5800
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0001-7678-4284
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Masao MatsuokaDepartment of Hematology, Rheumatology, and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID 0000-0002-0473-754X
Kenji IshitsukaDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.ORCID 0000-0002-7030-497X
Yuichi ShiraishiDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Satoru MiyanoM&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-7778-5374
B Hilda YeDepartment of Cell Biology, Albert Einstein College of Medicine, New York, NY; and.ORCID 0000-0002-2281-422X
Kazuya ShimodaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-2555-8188
Keisuke KataokaDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0002-8263-9902
University of Miyazaki · JPAlbert Einstein College of Medicine · USKyoto University · JPKumamoto University · JPImamura Hospital · JPKagoshima University Hospital · JPKeio University · JPNagasaki University · JPThe University of Tokyo · JPTokyo Medical and Dental University · JPJapanese Foundation For Cancer Research · JPJikei University School of Medicine · JPKawasaki Medical School · JPKumamoto Medical Center · JPUniversity of Miami · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Epigenetic Targeting of Afro-Caribbean Variant of HTLV-1 Related Adult T-cell Leukemia-lymphomaR01CA223232 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI RAMOS, JUAN CARLOS · 2018 to 2022
$1.7M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA223232
6 · The paper itself

Abstract

Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we performed whole-genome sequencing (WGS) of 150 ATL cases to reveal the overarching landscape of genetic alterations in ATL. We discovered frequent (33%) loss-of-function alterations preferentially targeting the CIC long isoform, which were overlooked by previous exome-centric studies of various cancer types. Long but not short isoform-specific inactivation of Cic selectively increased CD4+CD25+Foxp3+ T cells in vivo. We also found recurrent (13%) 3'-truncations of REL, which induce transcriptional upregulation and generate gain-of-function proteins. More importantly, REL truncations are also common in diffuse large B-cell lymphoma, especially in germinal center B-cell-like subtype (12%). In the non-coding genome, we identified recurrent mutations in regulatory elements, particularly splice sites, of several driver genes. In addition, we characterized the different mutational processes operative in clustered hypermutation sites within and outside immunoglobulin/T-cell receptor genes and identified the mutational enrichment at the binding sites of host and viral transcription factors, suggesting their activities in ATL. By combining the analyses for coding and noncoding mutations, structural variations, and copy number alterations, we discovered 56 recurrently altered driver genes, including 11 novel ones. Finally, ATL cases were classified into 2 molecular groups with distinct clinical and genetic characteristics based on the driver alteration profile. Our findings not only help to improve diagnostic and therapeutic strategies in ATL, but also provide insights into T-cell biology and have implications for genome-wide cancer driver discovery.

Indexed as

Gene Expression Regulation, NeoplasticMutationAnimalsAtaxin-1Biomarkers, TumorDNA Copy Number VariationsExome SequencingFemaleGenome, HumanHumansLeukemia-Lymphoma, Adult T-CellMiceMice, Inbred C57BLPrognosisProto-Oncogene Proteins c-relRepressor ProteinsAtaxin-1ATXN1 protein, humanBiomarkers, TumorCIC protein, humanProto-Oncogene Proteins c-relREL protein, humanRepressor Proteins

Identifiers

PMID34695199
PMCPMC8854674
OpenAlexW3210370843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.